ÂÜÀòÂÒÂ×

Terry brings nearly 20 years of biopharmaceutical experience and expertise in antimicrobial discovery authentically rooted in innovative genetic, genomic, chemical biology, and phenotypic screening strategies to identify novel targets and cognate antibiotic drug candidates to treat serious bacterial and fungal infections. Previously, Terry assumed increasing roles and responsibilities at Merck & Co., Inc. from 2004-2017, serving as Senior Research Fellow, Distinguished Scientist, and Co-Chair of the MRL Antibacterial Early Discovery Unit. Prior to joining Merck, he served as Director of Antifungal Research and Site Head of Elitra Canada, a subsidiary of Elitra Pharmaceuticals. Terry also served as a co-founder and Director of Research at Mycota Biosciences, an antifungal startup and later acquired by Elitra Pharmaceuticals. He has also served as principal investigator of two large-scale Genome Canada projects related to Candida albicans genomics and antifungal lead discovery. Terry has published over 80 peer-reviewed papers, reviews, and book chapters as well as multiple Merck, Elitra, and Mycota patents. Terry received his PhD in 1994 at McGill University in the laboratory of Dr. Howard Bussey where he studied yeast genetics and cell wall biogenesis, and was a post-doctoral fellow in the laboratory of Dr. Michael Snyder at Yale University.